M1002 is a hypoxia-inducible factor-2 ( HIF-2 ) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors. In Vitro M1002 (10 μM; 24 h) enhances the expression of HIF-2 target genes with great efficacy. M1002 (5 μM; 24 h) treatment shows synergy with prolyl hydroxylase domain (PHD) inhibitors. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: 786-O cells Concentration: 10 μM Incubation Time: 24 hours Result: Showed clear agonistic effects on the expression of HIF-2 target genes in 786-O cells as compared with the control. RT-PCRCell Line: Hep3B cells Concentration: 5 μM Incubation Time: 24 hours Result: Elevated the expression of EPO and NDRG1 by co-treatment of M1002 together with PHD inhibitors, compared with M1002 alone treatment. Form:Solid